Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...
An update from Septerna, Inc. ( (SEPN) ) is now available.
< SMaC combines EHLA-based coating with mechanical machining in one step. This speeds up the productio ... Copyright: © Fraunhofer ILT, Aachen, Germany.
The future of health innovation will not be defined by replacing existing medical models, but by strengthening biological regulation earlier—before pathology becomes visible.
The blueprint was developed through working groups and workshops hosted by the UK Textiles Pact during 2025, building on a cross-industry position statement released in summer 2025 by WRAP, the ...
The market is set for growth driven by bandwidth demands from advanced optics, data centers, and quantum networks. Integrated chips and phase-stable, low-voltage designs are pivotal as emerging ...
Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 – OMEICOS, a clinical-stage biopharmaceutical ...
Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in 2026. Learn why MAZE stock is a strong buy.
A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu.
Detailed price information for Janux Therapeutics Inc (JANX-Q) from The Globe and Mail including charting and trades.
A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling short of the bar Amgen set in another study, the biotech's stock halved in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results